Ravulizumab in Pregnancy Shows No New Safety Signals in Global Analysis
A global pharmacovigilance analysis of 354 pregnancies found no unexpected safety signals with the complement inhibitor ravulizumab, with outcomes consistent ...
A global pharmacovigilance analysis of 354 pregnancies found no unexpected safety signals with the complement inhibitor ravulizumab, with outcomes consistent ...
The final results of the German CARO study show that carfilzomib-based regimens achieve high adherence, trial-consistent effectiveness, and stable quality ...
A new real-world study of 144 US patients shows the first once-daily single-tablet macitentan/tadalafil combination for pulmonary arterial hypertension is ...
A large real-world study finds that GLP-1 receptor agonists are associated with significantly reduced risks of heart failure, pulmonary hypertension, ...
A nationwide analysis of French hospital cohorts finds that only about two-thirds of small-cell lung cancer patients eligible for G-CSF ...
A retrospective real-world study from Milan's San Raffaele institute compares ocrelizumab and ofatumumab as successor therapies for multiple sclerosis patients ...
A George Mason statistician has received FDA funding to develop regulatory-grade frameworks that quantify how record linkage errors affect the ...
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
A new systematic review finds that about one in five adults with diffuse large B-cell lymphoma develops febrile neutropenia during ...
A multicenter Central European real-world study finds sacituzumab govitecan delivers meaningful survival benefit and manageable toxicity in heavily pretreated metastatic ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine